SIETES :: 93213 citas

Resultados de la búsqueda por USO TERAPÉUTICO REFINAR BÚSQUEDA

1.

Abrams DI, Guzmán M. Can cannabis cure cancer?1. JAMA Oncology 2020:. [Ref.ID 103508]

2.

Sánchez Caballero D. "Es fundamental que el cannabis terapéutico sea aprobado para avanzar en la investigación" . eldiario.es 2019:5 de marzo. [Ref.ID 103049]

3.

Jones G. GW Pharma's cannabis-based medicine to be tested in dementia. PMLiVE 2019:1. [Ref.ID 103025]

4.

Sánchez Caballero D. La OMS recomienda sacar el cannabis de la lista de sustancias más peligrosas y acerca la regulación terapéutica. eldiario.es 2019:8 de febrero. [Ref.ID 103018]

5.

Sánchez Caballero D. El Gobierno da largas sobre la regulación del cannabis medicinal hasta que se pronuncie la OMS . eldiario.es 2019:28 de enero. [Ref.ID 103012]

6.

Anónimo. Synthetic cannabinoid may improve agitation and aggression in Alzheimer’s disease patients, research suggests. DIA Daily 2018:26 de julio. [Ref.ID 102724]

7.

Sánchez Caballero D. España mira para otro lado mientras cada vez más países regulan el uso del cannabis. eldiario.es 2018:30 de junio. [Ref.ID 102693]

8.

Joseph A. FDA approves country’s first medicine made from marijuana. STAT Daily Recap 2018:2. [Ref.ID 102664]

9.

Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM, for the GWPCARE3 Study Group. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med 2018;378:17 de mayo. [Ref.ID 102609]

10.

Gorelick DA. The effects of cannabis among adults with chronic pain. Ann Intern Med 2018;168:. [Ref.ID 102602]

11.

Anónimo. Australia becomes fourth nation to allow medicinal marijuana exports. DIA Daily 2018:4 de enero. [Ref.ID 102442]

12.

Whitlock J. Cannabis-derived drug granted priority review. San Diego Business Journal 2018:2 de enero. [Ref.ID 102441]

13.

Vélez AM. Juan Abelló pone a la venta su monopolio del opio en pleno debate sobre su venta descontrolada en EEUU . eldiario.es 2017:1. [Ref.ID 102121]

14.

O'Neil ME, Nugent SM, Morasco BJ, Freeman M, Low A, Kondo K, Zakher B, Elven C, Motu'apuaka M, Paynter R, Kansagara D. Benefits and harms of plant-based cannabis for posttraumatic stress disorder: a systematic review. Ann Intern Med 2017;167:332-40. [Ref.ID 102023]

15.

Nugent SM, Morasco BJ, O'Neil ME, Freeman M, Low A, Kondo K, Elven C, Zakher B, Motu'apuaka M, Paynter R, Kansagara D. The effects of cannabis among adults with chronic pain and an overview of general harms: a systematic review. Ann Intern Med 2017;167:319-31. [Ref.ID 102022]

16.

Russo EB. Cannabidiol claims and misconceptions. Trends Pharmacol Sci 2017;38:198-201. [Ref.ID 101988]

17.

Berkovic SF. Cannabinoids for epilepsy — Real data, at last. N Engl J Med 2017;376:2075-6. [Ref.ID 101596]

18.

Devinsky O, Cross JH, Laux L, Marsh E, Nabbout R, Scheffer IE, Thiele EA, Wright S, for the Cannabidiol in Dravet Syndrome Study Group. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017;376:2011-20. [Ref.ID 101595]

19.

Wong J, Motulski A, Abrahamowicz M, McGill J, Eguale T, Buckeridge DL, Tamblyn R. Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system. BMJ 2017;356:j603. [Ref.ID 101417]

20.

Morales DR, Guthrie B. Off-label prescribing of antidepressants. BMJ 2017;356:j849. [Ref.ID 101416]